Benzinga | Oct 13, 2021 01:38PM EDT

Taysha Gene Therapies Announces Sponsored Genetic Testing For Giant Axonal Neuropathy In Partnership With GeneDx As Well As A Collaboration with Hereditary Neuropathy Foundation And Charcot-Marie-Tooth Association Centers Of Excellence

GeneDx's Hereditary Neuropathy Panel will be available free of charge to individuals at risk for or suspected of having GAN

Taysha will collaborate with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence to increase disease awareness and access to testing

TSHA-120 is the first and only gene therapy to demonstrate clinical-stage arrest of disease progression at the 1.2x1014 and 1.8x1014 total vg dose

Clinical data for high dose 3.5x1014 total vg cohort expected in the second half of 2021 with regulatory feedback by year-end 2021

Estimated prevalence of patients with GAN is 2,400 in United States and Europe